Investigators reported that they generated neutrophils from human pluripotent stem cells and engineered these cells to express a chimeric antigen receptor directed at fibroblast activation protein (FAP). The source described increased reactive oxygen species-associated fluorescence when FAP CAR neutrophils were co-cultured with activated cardiac fibroblasts, indicating engagement and an oxidative burst. The study team observed dose-dependent cytotoxicity in 2D fibroblast cultures after CAR modification, with greater target-cell killing at higher effector-to-target ratios as summarized in the abstract. The authors did not provide full CAR construct sequences or detailed differentiation steps in the abstract; those methodological specifics were not reported in the source summary and require consulting the full text or supplementary materials.
The authors extended their assessment into 3D cardiac organoids. Data indicated that FAP CAR neutrophil treatment reduced fibroblast-associated fluorescence within organoids. At the same time, cardiomyocyte-associated cardiac troponin T staining showed no significant reduction, the authors noted, suggesting selective activity against fibrogenic cells rather than broad cytotoxicity against parenchymal cardiomyocytes. This observation aligns with the target choice—FAP being enriched on activated fibroblasts—but the abstract did not include quantitative measures of organoid contractility, electrophysiology, or long-term viability, and those endpoints were not reported in the source summary.
Compared with unmodified neutrophils, FAP CAR neutrophils exhibited higher inducible nitric oxide synthase (iNOS) expression and lower Arginase-1 expression, the authors reported. The study team interpreted this shift as consistent with an N1-associated polarization profile. Short, functional statements and mechanistic cues came through in the abstract: CAR modification changed marker expression and functional readouts linked to neutrophil activation. The source did not report extended immunophenotyping panels, cytokine secretion profiles, or time-course polarization dynamics in the abstract, so those details remain absent from the summary provided.
Authors examined public single-cell and single-nucleus RNA-sequencing datasets from human cardiac tissue to map temporal patterns of immune-associated gene expression and fibroblast activation. They used those temporal signatures to inform potential treatment timing for FAP CAR neutrophil delivery. The abstract did not list which datasets were queried, nor did it report specific marker genes or exact time points identified, so the precise transcriptomic evidence and analytic thresholds are not documented in the source summary. The study team nevertheless reported that these analyses contributed to the experimental rationale for in vivo interventions.
The authors tested systemic administration of FAP CAR neutrophils in a murine myocardial infarction (MI) model. In an exploratory comparison against PBS-treated controls, mice receiving FAP CAR neutrophils showed higher left ventricular ejection fraction at day 7, as reported in the abstract. The study team presented this as preliminary in vivo evidence that CAR-modified neutrophils can impact early post-MI function. The source explicitly states the work is a preprint and has not been peer reviewed. The abstract did not report animal cohort sizes, randomization methods, blinding, long-term cardiac remodeling outcomes, or safety signals such as off-target tissue damage or systemic inflammation; those elements were not provided in the abstract and therefore are not asserted here.
Limitations and immediate open questions documented in the source
The authors recognized that the findings require further evaluation. The report is a preprint and lacks peer review. The source did not report critical translational details in the abstract: dose schedules for animals, manufacturing scalability of hPSC-derived CAR neutrophils, CAR design specifics, persistent cell tracking, or extended safety and efficacy measures. Clinically relevant questions remain unanswered by the abstract, including whether selective fibroblast depletion will translate into durable functional improvement, potential on-target/off-tissue effects given FAP expression outside the heart, and how timing derived from transcriptomic signatures will perform across disease stages. These limitations were stated or implied in the source document and represent the next items readers should pursue in the full manuscript or follow-up studies.